DSIP: An Endogenous Sleep Peptide with an Unresolved Riddle at Its Core

The short version

DSIP stands for Delta Sleep-Inducing Peptide. It is a nine-amino-acid endogenous neuropeptide — your body actually makes it — first isolated from the cerebral venous blood of rabbits during electrically induced sleep. The researchers who named it, Schoenenberger and Monnier, observed that when this peptide was infused into the brains of recipient rabbits it appeared to enhance slow-wave (delta) brainwave activity. The name stuck.

Here is the honest part, and it matters: more than forty years of follow-up research have not resolved what DSIP actually does or how. A landmark 2006 review in the Journal of Neurochemistry summarized the situation bluntly — DSIP is a "still unresolved riddle" and the link between the peptide and sleep remains "extremely poorly documented and still weak" ^[9]. No DSIP receptor has been identified. No DSIP gene or biosynthetic precursor has been isolated. Its mechanism is genuinely unknown, and this is not a gap that should be glossed over.

A large share of people who try DSIP report no effect at all. This is the most important community signal, and it is here in the first section rather than buried in the caveats: one commonly repeated estimate is that DSIP produces a meaningful response in roughly half of those who try it, with the rest reporting nothing. Anyone reading this desk should weight that prominently. DSIP is not an approved drug, it is not intended for human consumption, and this page lists no dose.

What it is

DSIP is a linear nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). Its molecular formula is C₃₅H₄₈N₁₀O₁₅, and its International Nonproprietary Name is emideltide — though no emideltide drug product has ever been approved or marketed by any regulator.

A naturally occurring phosphorylated form, DSIP-P, is also described in the literature and is reported as more potent in some assays. DSIP is endogenous in the sense that it is found in the human body, particularly in the hypothalamus, limbic structures, pituitary gland, and various peripheral organs and tissues — but the absence of an identified gene or precursor means its biosynthesis remains unexplained. It is small enough to cross the blood-brain barrier via a saturable transport mechanism that is competitively inhibited by L-tryptophan ^[9]. Its reported plasma half-life in animals is only minutes, suggesting rapid degradation.

How it works

This section must begin with a clear statement: DSIP's mechanism of action is genuinely unknown. This is not a placeholder pending better research — it is the current scientific consensus after more than four decades of investigation. No specific DSIP receptor has been identified or cloned. No gene encoding a DSIP precursor has been found. A 2006 Journal of Neurochemistry review that examined the full body of literature concluded these gaps remain unresolved and characterized the sleep-promoting hypothesis as weakly documented ^[9].

What the literature has identified are associations — patterns that could reflect mechanism or could reflect secondary effects — including:

• A saturable blood-brain-barrier transport mechanism competitively inhibited by L-tryptophan, suggesting DSIP enters the brain via a specific transporter rather than by diffusion ^[9].
• A dopaminergic relay for the growth-hormone effect: DSIP-stimulated growth-hormone release in rat studies was blocked by the dopamine antagonist pimozide, implicating a dopaminergic pathway — but this finding did not replicate in human women, where no GH or prolactin response was seen ^[9].
• Proposed interaction with the endogenous opioid system, suggested by pilot data from opiate withdrawal studies, though this is mechanistically speculative ^[9].
• HPA axis modulation: intravenous DSIP significantly reduced plasma ACTH immunoreactivity in men for at least three hours, while cortisol was unaffected and followed its normal diurnal decline — suggesting some upstream neuroendocrine influence ^[11].

In 2024, a modified DSIP fusion peptide engineered with a blood-brain-barrier penetration sequence produced measurable effects in an insomnia mouse model: a ~31% reduction in wakefulness versus the insomnia model control, restoration of melatonin, serotonin and dopamine levels, anxiolytic and antidepressant behavioral effects, and increased hippocampal neuron density ^[8]. Importantly, the native unmodified DSIP was less effective than the fusion peptide in the same study — one of several indicators that structural analogues, not native DSIP, may be where the most pharmacologically actionable activity lies.

What the research shows

The 2006 critical review — the benchmark for honesty in this field. Kovalzon and Strekalova's Journal of Neurochemistry review remains the most important single document for understanding DSIP's evidence base ^[9]. Its findings: the original sleep-inducing observations have not been consistently reproduced; no specific receptor, gene, or precursor has been identified; the peptide's brain distribution (hypothalamus, limbic areas, pituitary) does not clearly map to sleep-regulation circuits; and synthetic analogues, not native DSIP, showed the clearest sleep-promoting effects in the studies that did work. The authors applied the word "riddle" deliberately.

Small human insomnia pilot (1981). Synthetic DSIP administered intravenously at 25 nmol/kg produced longer sleep duration, fewer nighttime interruptions, slightly more REM sleep, and no daytime sedation in six middle-aged chronic insomniacs ^[12]. Sleep-promoting effects appeared in the second hour after injection — there was a slight increase in arousal in the first hour. This is the primary human evidence for DSIP's sleep effects. It is a small, uncontrolled, decades-old pilot study, and it has not been repeated in a modern controlled trial.

Human ACTH modulation (1989). Intravenous DSIP at 25 nmol/kg in men produced a significant reduction in plasma ACTH-like immunoreactivity sustained for at least three hours, while cortisol followed its normal diurnal pattern without disruption ^[11]. The stress-hormone axis involvement — reducing ACTH without collapsing the cortisol response — is one of the more reproducible and mechanistically interpretable findings in the human literature.

Mouse lifespan and tumor study (2003). Monthly courses of a DSIP-containing preparation (Deltaran, given at approximately 100 µg/kg for five consecutive days per month) in female SHR mice increased maximum lifespan by 24.1%, extended late-survival lifespan by 17.1%, reduced spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% ^[10]. This is striking data from a mouse model. It originates from a small set of related Russian research groups and requires independent replication before any strong claim can be built on it.

2024 fusion-peptide mouse study. A blood-brain-barrier-penetrating DSIP fusion peptide reduced wakefulness by ~31% in PCPA-induced insomnia mice, restored multiple monoamine and melatonin parameters, and produced anxiolytic and antidepressant effects — but native DSIP was inferior in the same experiment ^[8]. The study is recent and well-characterized, but its relevance to unmodified DSIP sold as a research chemical is limited.

Reported effects, cautions & safety

A note on this section. Community-reported effects below are explicitly anecdotal, not clinical evidence. They describe what people say; they do not establish that DSIP caused any effect, that effects were real rather than expectation-driven, or that use was safe. Safety cautions come from mechanism and the cited literature.

---

What people report (anecdotal, not clinical evidence):

The most important signal is the one that runs counter to expectation: a large share of people report no effect at all. Community practitioners estimate DSIP produces a meaningful response in roughly half of those who try it. Forums contain a substantial share of reports saying "didn't notice anything" or "finished a vial and felt nothing." This non-response is not a rumor or a minority position — it is a major strand of community experience, and it belongs here, prominently, ahead of any list of reported benefits.

Among those who do respond, the most commonly described effects are:

• Falling asleep faster and a smoother wind-down — a quieter mind, fewer racing thoughts, a sense of readiness for sleep rather than being knocked out. Described consistently as subtle, not a sedative hit.
• Deeper, more restorative-feeling sleep — sleeping more heavily, waking less, and feeling the same hours of sleep were "worth more." Some cite wearable-tracker data showing more deep sleep, though forum trackers are not clinical measurements.
• Waking clear-headed, without grogginess — one of the most praised reported features, frequently contrasted with the next-day heaviness people associate with melatonin or prescription sleep aids.
• Vivid, memorable dreams — very commonly reported, including by people who do not normally recall dreaming. Most find it pleasant or neutral; a minority find intense dream content disruptive enough to wake them.
• A calmer, lower-stress feeling or easier ability to switch off — described as a volume-reduction on racing thoughts rather than sedation. Softer and more variable than the sleep signal.

Adverse and mixed signals are real and important:

• Unpredictable and delayed timing. Several people describe sedation arriving the next day during work hours rather than the night of use, and others report multi-day carry-over effects. The timing felt genuinely hard to manage.
• Next-day grogginess. A meaningful minority report heavy-headed or slow mornings — directly contradicting the "no hangover" reports and underscoring how individual the response is.
• Headache is the most commonly reported side effect, described as usually mild and transient, but one forum account described a headache lingering for days after stopping.
• Mild nausea, dizziness, or lightheadedness are occasionally reported, echoing the transient headache and vertigo noted in older human clinical reports.
• Diminishing effect with nightly use — community practice tends to favor intermittent rather than continuous use, which is consistent with some kind of tolerance or adaptation.
• "Feels weak if you expect a sedative knockout" — a common source of disappointment. People who approach DSIP expecting it to function like a prescription hypnotic consistently feel it failed; people who expect a gentle nudge report better experiences.

---

Safety cautions (drawn from the literature):

• Research chemical supply only. DSIP is not an approved drug anywhere; no emideltide product has ever been approved or marketed. Material sold as a research chemical carries no pharmaceutical quality, purity, dose-accuracy, or sterility guarantee ^[9].
• Its mechanism is unknown, so interactions are unpredictable. When the basic mechanism is unidentified — no receptor, no gene — there is no rational basis for predicting how DSIP might interact with medications, supplements, or medical conditions. The parabolic dose-response noted in some animal work (more is not reliably stronger) further complicates any dosing logic ^[9].
• Essentially no long-term human safety data. Human study is limited to small 1980s pilots and a single ACTH modulation experiment; no large or long-duration controlled human safety study exists ^[11][12].
• Using an unproven peptide to chase sleep can mask a real sleep disorder. Persistent insomnia can reflect treatable underlying conditions — sleep apnea, circadian disorder, depression, thyroid dysfunction. Relying on an unproven research chemical risks delaying a real diagnosis ^[12][9].
• Combining with sedatives, sleep aids, or alcohol is untested. DSIP has been studied as an adjunct in anesthesia contexts and was proposed to interact with the opioid system in withdrawal pilot work; stacking an agent with an unknown mechanism on top of other CNS-depressant substances has never been formally tested ^[9].
• Effects on pregnancy and pre-existing medical conditions are unknown — there are no data, and DSIP's reported involvement in stress-hormone and neuroendocrine signaling means the consequences in these populations cannot be predicted from the available evidence ^[9][11].

Where it fits in this desk

DSIP occupies the most honest and in some ways most instructive position on this desk: a compound whose name comes from a real experimental observation, whose endogenous status gives it theoretical plausibility, and whose four-decade research career has still not explained what it does or how. It sits in useful contrast to Selank, which has at least a proposed and partially characterized mechanism. Reading them together is a good illustration of how uneven the evidence base in peptide research can be — and why "interesting" is not the same as "established." See the comparison page for the side-by-side.